"POBA Plus" will the balloon regain its luster?

Circulation

Volumn 118, Issue 13, 2008, Pages 1309-1311

  Henry, Timothy D ^a   Schwartz, Robert S ^a   Hirsch, Alan T ^a,b  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Angioplasty; Editorials; Peripheral vascular disease; Pharmacology

Indexed keywords

CONTRAST MEDIUM; PACLITAXEL; ANTINEOPLASTIC AGENT; BIOMATERIAL;

ANGINA PECTORIS; ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG MECHANISM; DRUG RELEASE; EDITORIAL; FEMORAL ARTERY; HEALTH CARE COST; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; LEG REVASCULARIZATION; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; METHODOLOGY; NOTE; PERIPHERAL VASCULAR DISEASE;

ANGIOPLASTY, BALLOON; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COATED MATERIALS, BIOCOMPATIBLE; HUMANS; PACLITAXEL; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 54049110768     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.797498     Document Type: Editorial

References (8)

1. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease [Lower Extremity, Renal, Mesenteric, and Abdominal Aortic]). Circulation. 2006;113:1474-1547.
2. Hirsch AT, Hartman L, Town RJ, Virnig BA. National health care costs of peripheral arterial disease in the Medicare population. Vasc Med. 2008;13:209-215.
3. Hirsch AT. Treatment of peripheral arterial disease: extending "intervention" to "therapeutic choice." N Engl J Med. 2006;354:1944-1947.
4. Werk M, Langner S, Reinkensmeier B, Boettcher H-F, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: Femoral Paclitaxel randomized pilot trial. Circulation. 2008;118;1358-1365.
5. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689-699.
6. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355:2113-2124.
7. Malenka DJ, Kaplan AV, Lucas FL, Sharp SM, Skinner JS. Outcomes following coronary stenting in the era of bare-metal vs the era of drug eluting stents. JAMA. 2008;299:2868-2876.
8. Schwartz RS, Henry TD. Pathophysiology of coronary artery restenosis. Rev Cardiovasc Med. 2002;3(suppl 5):S4-S9.